• Company
  • Public Affairs
  • Muscular Dystrophy Association

MDA stands for Muscular Dystrophy Association, which was established in November 1999. Guided by its mottos “Since our patients are unable to stand on their own, conservators must help them” and “As a parent who shares in the pain, let us love and protect other patients like our own children,” MDA also visits and supports researchers of muscular dystrophy, a rare disease.
Macrogen has been assisting MDA activities by letting its employees keep in close contact with patients, especially in young age, by holding various events such as annual concert where both patients and employees participate, and annual spring picnic and so on. In addition, Macrogen has been funding part of MDA's activities with the hope of better future for patients.

Muscular dystrophy refers to a group of disorders characterized by progressive muscle weakness, necrosis and regeneration of muscle that are detected through muscle tissue examination, uneven size of muscle fibers, and replacement of necrosised muscle fibers with adipose and fibrous tissues. Although biopsy opinions are similar, hereditary factors vary. In general, symptoms such as difficulty in standing, walking, and running due to progressive muscle weakness develop. Therefore, carrying out a diagnosis according to hereditary factors with only the symptoms is difficult. The most common muscular dystrophies are Duchenne/Becker muscular dystrophies (DMD/BMD). For the hereditary factors of this disease, the discovery of dystrophin, one of fascia proteins, and dystrophin gene led to a breakthrough in understanding the pathophysiology of muscular dystrophy. In addition to several types of muscular dystrophies classified according to the existing clinical aspects, the causal proteins and genes of about 20 muscular dystrophies have become known through such scientific progress.

Showing an incidence rate of 1 out of 3,300~3,500 men after birth and falling under an X chromosome-association muscular dystrophy, Duchenne/Becker muscular dystrophies account for about 90% of hereditary muscle disorders. Depending on the seriousness of clinical aspects, types of muscular dystrophy are classified into Duchenne and Becker muscular dystrophies. In particular, the symptoms of Duchenne muscular dystrophy are the delayed development of muscle motor skills (in most cases, independent walking is impossible until 18 months), frequent slips (at the age of 4-5), and difficulty in tiptoeing or climbing stairs. In most cases, the calf muscle shows false hypertrophy (in actuality, muscles do not become portly; instead, adipose and fibrous tissues are developed in the region of necrosised muscle tissues such that muscles seem hard and large), and muscle weakness begins to develop rapidly in the muscle region of the lower limbs. As a result, the patient is unable to walk independently at the age of about 10, relying on a wheelchair instead. On the other hand, clinical aspects and age of onset of Becker muscular dystrophy vary: attack of the disease at the age of 6-19, muscle weakness of the lower limbs, and muscle pain or spasm of the calf muscle. Becker muscular dystrophy develops slower than Duchenne muscular dystrophy. The development pace also varies. As the causal gene, dystrophin is the largest known single-disease gene, consisting of about 2,500,000 bases and about 79 exons (gene pieces). In terms of hereditary factors, 50-60% of the disease attack rate is caused by the deletion of gene; the other 40-50% is caused by point mutation, minute deletion or duplication, etc.